Dose Reduced Induction Therapy (A)-AIDA in Patients with Acute Myeloid Leukemia, Being Unfit for Standard 7+3 Chemotherapy and Literature Review of Acute Myeloid Leukemia Treatment in Unfit/Older AML Patients
Recent studies established HMA/VEN as first-line treatment for older/frail AML patients. Because (A)-AIDA is equally effective in patients with secondary or relapsed AML or ECOG >1, this regimen is an interesting treatment option for patients uneligible to HMA/VEN regimens.
Authors
- Peter Brossart (ORCID: https://orcid.org/0009-0002-9324-5527)
- Marie von Lilienfeld‐Toal (ORCID: https://orcid.org/0000-0002-9756-3541)
- Corinna Hahn‐Ast
- L Birk
- Katjana Schwab (ORCID: https://orcid.org/0000-0002-6916-2900)
- Axel Glasmacher (ORCID: https://orcid.org/0000-0003-2611-7656)
- Karin Mayer (ORCID: https://orcid.org/0000-0001-7223-9748)
- Ingo G. H. Schmidt-Wolf (ORCID: https://orcid.org/0000-0002-5655-0867)
Institutions
- University Hospital Bonn (DE)
- Ruhr University Bochum (DE)
Publication Details
- Journal
- Acta Haematologica
- Published
- 2025-05-05
- DOI
- https://doi.org/10.1159/000545792
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00